Dissemination of SHV-12 and Characterization of New AmpC-Type Beta-Lactamase Genes among Clinical Isolates of
            <i>Enterobacter</i>
            Species in Korea

Lee, Sangeun; Kim, Jae Young; Shin, Sang Heum; An, Young Jun; Choi, Young Wook; Jung, Yeun Chang; Jung, Ho Sang; Sohn, Eui Suk; Jeong, Seok Hoon; Lee, Kye Joon

doi:10.1128/jcm.41.6.2477-2482.2003

Cited by 26 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, the proportion of ESBL-producing isolates was even higher (15%, 25%, and 37%, respectively) in intensive care units than elsewhere. SHV-12 remained the most prevalent type of ESBL among Enterobacter cloacae, which was in agreement with previous findings (13,27).…”

Section: Discussionsupporting

confidence: 82%

Development of a Multiplex PCR and SHV Melting-Curve Mutation Detection System for Detection of Some SHV and CTX-M β-Lactamases of Escherichia coli , Klebsiella pneumoniae , and Enterobacter cloacae in Taiwan

Chia

Chu

et al. 2005

J Clin Microbiol

View full text Add to dashboard Cite

Infection by extended-spectrum ␤-lactamase (ESBL)-producing Enterobacteriaceae has been increasing in Taiwan. Accurate identification of the ESBL genes is necessary for surveillance and for epidemiological studies of the mode of transmission in the hospital setting. We describe herein the development of a novel system, which consists of a multiplex PCR to identify bla SHV , bla CTX-M-3 -like, and bla CTX-M-14 -like genes and a modified SHV melting-curve mutation detection method to rapidly distinguish six prevalent bla SHV genes (bla SHV-1 , bla SHV-2 , bla SHV-2a , bla SHV-5 , bla SHV-11 , and bla SHV-12 ) in Taiwan. Sixty-five clinical isolates, which had been characterized by nucleotide sequencing of the bla SHV and bla CTX-M genes, were identified by the system. The system was then used to genotype the ESBLs from 199 clinical isolates, including 40 Enterobacter cloacae, 68 Escherichia coli, and 91 Klebsiella pneumoniae, collected between August 2002 and March 2003. SHV-12 (80 isolates) was the most prevalent type of ESBL identified, followed in order of frequency by CTX-M-3 (65 isolates) and CTX-M-14 (36 isolates). Seventeen (9%) of the 199 clinical isolates harbored both SHV-and CTX-M-type ESBLs. In contrast toEnterobacter cloacae, the majority of which produced SHV-type ESBLs, E. coli and K. pneumoniae were more likely to possess CTX-M-type ESBLs. Three rare CTX-M types were identified through sequencing of the bla CTX-M-3 -like (CTX-M-15) and bla CTX-M-14 -like (CTX-M-9 and CTX-M-13) genes. The system appears to provide an efficient differentiation of ESBLs among E. coli, K. pneumoniae, and Enterobacter cloacae in Taiwan. Moreover, the design of the system can be easily adapted for similar purposes in areas where different ESBLs are prevalent.

show abstract

Section: Discussionsupporting

confidence: 82%

Development of a Multiplex PCR and SHV Melting-Curve Mutation Detection System for Detection of Some SHV and CTX-M β-Lactamases of Escherichia coli , Klebsiella pneumoniae , and Enterobacter cloacae in Taiwan

Chia

Chu

et al. 2005

J Clin Microbiol

View full text Add to dashboard Cite

show abstract

“…A 99.5% homology with the A. cloacae K9973-β-lactamase AmpC gene sequence was identified. The overall length of A. cloacae K9973-β-lactamase AmpC gene sequence was 1,165 bp, consistent with the gene sequence of A. cloacae K9973-generating CMY-7 AmpC enzyme previously identified by Lee et al (24). The present study is the first reported identification of plasmid-mediated AmpC β-lactamase expression in P. aeruginosa.…”

Section: Discussionsupporting

confidence: 70%

Study on drug resistance of Pseudomonas aeruginosa plasmid-mediated AmpC β-lactamase

Zhu

Zhang

Huang

et al. 2012

Molecular Medicine Reports

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the resistance of plasmid-mediated AmpC β-lactamase in Pseudomonas aeruginosa, to detect and identify the AmpC genotype and to provide evidence for antibiotic applications in the clinic. Resistance phenotype in 108 strains of clinically isolated P. aeruginosa was determined by Kirby-Bauer disk test and cefoxitin three dimensional test in AmpC-positive strains. Plasmids were extracted from AmpC-positive strains using the SDS-alkali splitting technique. The depurated plasmid was used to amplify AmpC β-lactamase genes by PCR. Positive PCR products were sequenced by the Shanghai Sangon Biological Engineering Technology Company. Gene homology of PCR products with other index sample gene sequences was compared. In the present study, 28 AmpC enzyme-positive P. aeruginosa strains among 108 were identified. Multidrug-resistance to antibiotics was observed in positive AmpC P. aeruginosa strains and a new P. aeruginosa strain of plasmid-mediated CMY-7 type AmpC enzyme was identified. In addition, AmpC type β-lactamases were revealed to be important in the resistance mechanism to antibiotics in P. aeruginosa. This is the first report of CMY-7 plasmid-mediated AmpC enzyme expression in P. aeruginosa. IntroductionThe increasing use and application of broad-spectrum antibiotics has led to increased reports of bacterial drug resistance and clinical infection. At present, drug-resistant bacteria, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, vancomycinresistant Enterococcus, multidrug-resistant Baumanii, Klebsiella pneumoniae, Escherichia coli and Pseudomonas aeruginosa are increasingly being detected in clinical and laboratory settings (1). Appearance of pan-resistant bacteria, including Cray Borrelia, which produces New Delhi Metallo β-lactamase-1, an enzyme responsible for generating resistance (2), is causing an even greater challenge to humans. Therefore, study of clinical bacterial drug resistance and mechanisms and the development of solutions to bacterial resistance is important. Previously, Gram-negative bacilli AmpC β-lactamase was understood to be generated by chromosome mediation only. However, Papanicolaou et al (3) identified plasmid-mediated AmpC β-lactamase (MIR-1) in a strain of Cray Borrelia bacterium isolated from a patient in Rhode Island Hospital (USA) in 1989. Following this, the plasmid-mediated AmpC enzyme was rapidly identified in a number of other countries. At present, more than 20 plasmid-mediated AmpC enzymes have been identified. The plasmid-mediated AmpC enzyme is resistant to antibiotics, enabling the plasmid to continue to express the protein at high levels and carry multiple drug-resistant genes. Plasmid-mediated drug resistance is transmitted between members of the same or different bacterial species. Transmission is rapid and performed at a range of distances. Therefore, understanding of the mechanism and elucidation of solutions to plasmid-mediated AmpC enzyme resistance is crucial...

show abstract

“…ESBLs of the SHV-2, SHV-5, and SHV-12 lineage initially dominated in those studies in which genotypic characterization has been carried out (209). Newly described SHV-type ESBLs have recently been reported from Taiwan and Japan (82,202).…”

Section: Global Epidemiologymentioning

confidence: 99%

Extended-Spectrum β-Lactamases: a Clinical Update

2005

View full text Add to dashboard Cite

SUMMARY Extended-spectrum β-lactamases (ESBLs) are a rapidly evolving group of β-lactamases which share the ability to hydrolyze third-generation cephalosporins and aztreonam yet are inhibited by clavulanic acid. Typically, they derive from genes for TEM-1, TEM-2, or SHV-1 by mutations that alter the amino acid configuration around the active site of these β-lactamases. This extends the spectrum of β-lactam antibiotics susceptible to hydrolysis by these enzymes. An increasing number of ESBLs not of TEM or SHV lineage have recently been described. The presence of ESBLs carries tremendous clinical significance. The ESBLs are frequently plasmid encoded. Plasmids responsible for ESBL production frequently carry genes encoding resistance to other drug classes (for example, aminoglycosides). Therefore, antibiotic options in the treatment of ESBL-producing organisms are extremely limited. Carbapenems are the treatment of choice for serious infections due to ESBL-producing organisms, yet carbapenem-resistant isolates have recently been reported. ESBL-producing organisms may appear susceptible to some extended-spectrum cephalosporins. However, treatment with such antibiotics has been associated with high failure rates. There is substantial debate as to the optimal method to prevent this occurrence. It has been proposed that cephalosporin breakpoints for the Enterobacteriaceae should be altered so that the need for ESBL detection would be obviated. At present, however, organizations such as the Clinical and Laboratory Standards Institute (formerly the National Committee for Clinical Laboratory Standards) provide guidelines for the detection of ESBLs in klebsiellae and Escherichia coli. In common to all ESBL detection methods is the general principle that the activity of extended-spectrum cephalosporins against ESBL-producing organisms will be enhanced by the presence of clavulanic acid. ESBLs represent an impressive example of the ability of gram-negative bacteria to develop new antibiotic resistance mechanisms in the face of the introduction of new antimicrobial agents.

show abstract

Dissemination of SHV-12 and Characterization of New AmpC-Type Beta-Lactamase Genes among Clinical Isolates of Enterobacter Species in Korea

Cited by 26 publications

References 22 publications

Development of a Multiplex PCR and SHV Melting-Curve Mutation Detection System for Detection of Some SHV and CTX-M β-Lactamases of Escherichia coli , Klebsiella pneumoniae , and Enterobacter cloacae in Taiwan

Development of a Multiplex PCR and SHV Melting-Curve Mutation Detection System for Detection of Some SHV and CTX-M β-Lactamases of Escherichia coli , Klebsiella pneumoniae , and Enterobacter cloacae in Taiwan

Study on drug resistance of Pseudomonas aeruginosa plasmid-mediated AmpC β-lactamase

Extended-Spectrum β-Lactamases: a Clinical Update

Contact Info

Product

Resources

About